Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

Authors: Cathy Zhou, Zilong Yuan, Weijie Ma, Lihong Qi, Angelique Mahavongtrakul, Ying Li, Hong Li, Jay Gong, Reggie R. Fan, Jin Li, Michael Molmen, Travis A. Clark, Dean Pavlick, Garrett M. Frampton, Brady Forcier, Elizabeth H. Moore, David K. Shelton, Matthew Cooke, Siraj M. Ali, Vincent A. Miller, Jeffrey P. Gregg, Philip J. Stephens, Tianhong Li

Source: Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-13 (2018)

Subject Terms: Next-generation sequencing (NGS), Plasma, Cell-free DNA (cfDNA), Circulating tumor DNA (ctDNA), Genomic alterations (GAs), Maximum somatic allele frequency (MSAF), Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s13045-018-0671-8; https://doaj.org/toc/1756-8722

Access URL: https://doaj.org/article/f7a6b3e50e784343a7af265214bc7dc3